Andrew Lenz

Andrew Lenz is an experienced professional in global forecasting and biopharmaceuticals, currently serving as the Director of Global Forecasting at Apellis Pharmaceuticals since December 2019. Previously, Andrew held various roles at Biogen, including Associate Director and head of US Forecasting, where responsibilities spanned annual and long-range patient forecasts across multiple therapeutic areas. With a strong background in process analytics and forecasting, Andrew also contributed to the manufacturing sciences at Biogen. Andrew's career began at Merck, where positions included Staff Biochemical Engineer in bioprocess development. Andrew earned a Master of Science in Finance and an MBA from D'Amore-McKim School of Business at Northeastern University and holds a Bachelor of Science in Chemical Engineering from Princeton University.